PubMed Health⌕ Search

Biomedical subjects

N Zisapel

Publications and source records attributed to N Zisapel.

At least 19 recordsLinked to original sources
PubMed1995

Improvement of sleep quality in elderly people by controlled-release melatonin.

Melatonin, produced by the pineal gland at night, has a role in regulation of the sleep-wake cycle. Among elderly people, even those who are healthy, the frequency of sleep disorders is high and there is an association with impairment of melatonin production. We investigated the effect of a controlled-release formulation of melatonin on sleep quality in 12 elderly subjects (aged 76 [SD 8] years) who were receiving various medications for chronic illnesses and who complained of insomnia. In all 12 subjects the peak excretion of the main melatonin metabolite 6-sulphatoxymelatonin during the night was lower than normal and/or delayed in comparison with non-insomniac elderly people. In a randomised, double-blind, crossover study the subjects were treated for 3 weeks with 2 mg per night of controlled-release melatonin and for 3 weeks with placebo, with a week's washout period. Sleep quality was objectively monitored by wrist actigraphy. Sleep efficiency was significantly greater after melatonin than after placebo (83 [SE 4] vs 75 [3]%, p < 0.001) and wake time after sleep onset was significantly shorter (49 [14] vs 73 [13] min, p < 0.001). Sleep latency decreased, but not significantly (19 [5] vs 33 [7] min, p = 0.088). Total sleep time was not affected. The only adverse effects reported were two cases of pruritus, one during melatonin and one during placebo treatment; both resolved spontaneously. Melatonin deficiency may have an important role in the high frequency of insomnia among elderly people. Controlled-release melatonin replacement therapy effectively improves sleep quality in this population.

Aged↗
PubMed1995

Modulation by melatonin of protein secretion from melanoma cells: is cAMP involved?

The pineal hormone melatonin modulates constitutive protein secretion from melanoma M2R cells. Nanomolar concentrations of melatonin inhibited protein secretion early after plating or at low cell density, but facilitated it late after plating or at high cell density. Inhibition by melatonin of adenylate cyclase is the best known downstream response to melatonin. We have therefore examined the involvement of cAMP in the melatonin-mediated modulation of protein secretion from the melanoma cells. Melatonin slightly but significantly reduced cell cAMP content when effecting inhibition and marginally increased cAMP levels when effecting facilitation of protein secretion. Dibutyryl cAMP abrogated the melatonin-mediated inhibition but not facilitation of protein secretion without affecting basal secretion. Accordingly, forskolin prevented the inhibitory action of melatonin on protein secretion without affecting basal secretion. The selective protein kinase A inhibitor H-89 did not alter the inhibitory effect of melatonin at low cell density and slightly facilitated secretion at high cell density with or without melatonin. Thus, melatonin's effects on protein secretion may not be mediated via cAMP. Nevertheless, changes in cAMP or protein kinase A activity can abrogate, or mask, the melatonin-mediated responses.

Animals↗
PubMed1995

Effects of long-term administration of melatonin and a putative antagonist on the ageing rat.

Adult rats were treated with either melatonin, the putative melatonin antagonist N-(2,4 dinitrophenyl)-5-methoxytryptamine (ML-23), their combination, or a vehicle for 16 months via the drinking water. The survival rates, serum testosterone and densities of 125I-melatonin binding sites in the medulla-pons and hypothalamus of the animals at the age of 27-29 months were significantly higher in the melatonin than vehicle-treated group. Surprisingly, ML-23 without or with melatonin, also prolonged the life-span of the aged animals. ML-23 treatment greatly increased 125I-melatonin binding in the medulla-pons whereas this increase was prevented by melatonin supplementation. Thus melatonin can attenuate age-related decrease in survival rates, testosterone and brain 125I-melatonin binding sites, while chronic blockade by the putative antagonist also elicits melatonin-mimetic responses, perhaps by effecting supersensitivity.

5-Methoxytryptamine↗
PubMed1995

Facilitation and inhibition of G-protein regulated protein secretion by melatonin.

Melatonin has been found to inhibit or enhance the constitutive secretion of proteins from the cultured melanoma cells at nanomolar concentrations (0.5-10 nM), in a dose dependent manner. The amplitude and direction of the response were found to depend on cell density: melatonin inhibited the release early after plating or at low cell density, but facilitated the release later on, or at high cell density. To elucidate the involvement of G-proteins in these responses, the effects of guanosine 5'-O-(3-thiotriphosphate) (GTP tau S; which was introduced into the cells during the process of permeabilization and resealing with ATP), aluminum fluoride, pertussis and cholera toxins on protein secretion from the cells were assessed in the absence and presence of melatonin. At low cell density, melatonin inhibited release, but paradoxically enhanced it when GTP hydrolysis was blocked (by GTP tau S or cholera toxin treatment). Aluminum fluoride and melatonin inhibited protein release in the absence or presence of GTP tau S. At high cell density, melatonin facilitated the release and so did GTP tau S, aluminum fluoride, their combination, and cholera toxin treatment. However, in the presence of the combination of GTP tau S, aluminium fluoride and melatonin, protein release was paradoxically inhibited. Similar treatment of the cells with pertussis toxin, did not affect the melatonin-mediated inhibition or facilitation. These results indicate that the effects of melatonin on protein secretion are mediated by at least one heterotrimeric G protein which belongs to the Gs class. In addition, melatonin can facilitate secretion via a cholera and pertussis toxins-insensitive mechanism which can be inhibited by aluminum fluoride. This effect is manifested when Gs is permanently activated (by GTP tau S or cholera toxin).

Aluminum Compounds↗
PubMed1992

Modification by oxazepam of the diurnal variations in brain 125I-melatonin binding sites in sham-operated and pinealectomized rats.

Sham-operated and pinealectomized male rats were maintained at 14 h light:10 h dark cycles (lights-on 5.00 h) and injected daily, for 14 days, with oxazepam or vehicle. 125I-melatonin binding was recorded in synaptosomes prepared at 10.00, 18.00, and 24.00 h from the hypothalamus, hippocampus and medulla-pons of the rats. In the sham-operated, vehicle treated rats, specific 125I-melatonin binding in all brain areas studied was higher at 18.00 h, whereas in the oxazepam-treated animals, binding was higher at 24.00 h than at the other times tested. In the pinealectomized, vehicle-treated rats, the binding recorded at 18.00 h in all three brain areas, was lower than at the other times of day tested. Oxazepam treatment decreased 125I-melatonin binding at 24.00 h in the hippocampus and medulla-pons of the pinealectomized rats and did not significantly affect the binding in the hypothalamus. These results indicate the ability of oxazepam, pinealectomy and their combination, to manipulate the diurnal variations in 125I-melatonin binding sites in the rat brain.

Animals↗
PubMed1991

Melatonin binding proteins identified in the rat brain by affinity labeling.

N-Bromoacetyl-2-iodo-5-methoxytryptamine (BIM), a novel derivative of the biologically active melatonin analog, 2-iodomelatonin, was prepared and used to identify melatonin binding proteins in rat brain synaptosomes. Incubation of the synaptosomes with BIM resulted in a time and concentration dependent, irreversible inhibition of 2-[125I]iodomelatonin binding. In parallel, the radioactive form of BIM, N-bromoacetyl-2-[125I]iodo-5-methoxytryptamine ([125I]BIM) became incorporated into the synaptosomes. The incorporation of [125I]BIM was inhibited by BIM, 2-iodomelatonin and melatonin but not by 5-methoxytryptamine or N-acetyl serotonin. [125I]BIM became covalently attached to three polypeptides with apparent molecular weight values of 92, 55 and 45 kDa; the labeling of all three proteins was markedly inhibited by melatonin. These results indicate that the 92, 55 and 45 kDa polypeptides are melatonin binding proteins.

Affinity Labels↗
PubMed1991

Affinity labeling of melatonin binding sites in the hamster brain.

N-Bromoacetyl-2-iodo-5-methoxytryptamine (BIM), a novel derivative of the biologically active melatonin analog, 2-iodomelatonin, was used to identify melatonin binding proteins in synaptosomes from Syrian hamster brain. Incubation of the synaptosomes with BIM resulted in a concentration dependent, irreversible inhibition of 2-125I-iodomelatonin binding. The radioactive form of BIM, N-Bromoacetyl-2-125I-iodo-5-methoxytryptamine (125I-BIM), became covalently attached to three proteins in the synaptosomes, in a concentration dependent manner. These proteins had apparent molecular weight values of 92, 55 and 45 kilodaltons. The incorporation of 125I-BIM into all three proteins was inhibited by BIM greater than 2-iodomelatonin greater than melatonin whereas the melatonin antagonist N-(1,4 dinitrophenyl)- 5-methoxytryptamine (ML-23) selectively inhibited the labeling of the 45 kDa protein. These results indicate that the 92, 55 and 45 KDa polypeptides are melatonin binding proteins.

5-Methoxytryptamine↗
PubMed1991

Castration affects brain iodomelatonin binding in hamsters maintained in long but not short days.

The effects of castration on 2-[125I]iodomelatonin ([125I]melatonin) binding sites in discrete brain areas were investigated in male Syrian hamsters exposed to long and short days. In hamsters maintained in long days (14 h light: 10 h darkness), castration produced a marked decrease in [125I]melatonin binding in the brain, particularly in the medulla-pons hypothalamus and hippocampus. Maximal response in the medulla-pons and hypothalamus was observed at 3 days; specific [125I]melatonin binding subsequently increased to reach control levels within 30 days after castration. In the hippocampus, the decrease in [125I]melatonin binding was still evident at 90 days after castration and could be reversed by testosterone. Exposure to short days (8 h light: 16 h darkness) did not affect [125I]melatonin binding in the various brain areas of the intact hamsters; even after 90 days when circulating testosterone decreased to castrated levels, the binding remained as in intact, long-day-housed controls. Moreover, [125I]melatonin binding in the various brain areas of hamsters exposed to short days was unaffected by castration. The results clearly indicate that the regulation by testosterone of melatonin receptors in the medulla-pons, hypothalamus and hippocampus of the male hamster depends on the prevailing photoperiod.

Animals↗
PubMed1989

Diurnal variations in melatonin binding sites in the hamster brain: impact of melatonin.

The distribution of 125I-melatonin binding sites in the male Syrian hamster brain was recorded at 3 times over a 24 h period. The binding in the hypothalamus, hippocampus, medulla-pons and midbrain of the hamsters varied significantly over the 24 h period with different patterns and phases. No such variations were observed in the parietal cortex. Daily morning (10.00 h) or late afternoon (18.00 h) injections of melatonin for 28 days markedly increased the serum concentrations of melatonin at all times recorded. Serum concentrations of testosterone were significantly lower in animals injected with melatonin in the late afternoon than in the untreated controls; no such decrease was observed in animals injected in the morning despite the continuously elevated levels of circulating melatonin. The daily melatonin injections did not significantly affect 125I-melatonin binding in the hypothalamus, parietal cortex and medulla-pons. In the midbrain, 125I-melatonin binding decreased regardless of the time of injection. In the hippocampus, morning melatonin injections caused a marked decrease in 125I-melatonin binding at all times recorded whereas melatonin injected in the late afternoon led to a decrease in 125I-melatonin binding at 10.00 h only. These results indicate diurnal variations in 125I-melatonin binding sites in discrete brain areas of the golden hamster, persisting despite prolonged duration of elevated levels of circulating melatonin. The differential effects of timed melatonin injections on the hippocampal 125I-melatonin binding sites are positively correlated with the counter-antigonadal response produced by morning melatonin injections.

Animals↗
PubMed1989

A novel melatonin antagonist, N-(2,4-dinitrophenyl)-5-methoxytryptamine neutralizes some effects of melatonin in the female Syrian hamster.

In this present study we evaluated the ability of a recently synthesized melatonin antagonist, N-(2,4-dinitrophenyl)-5-methoxytryptamine (ML-23), to antagonize the effects of afternoon injections of melatonin on the reproductive and thyroid axes in the female Syrian hamster. Thirty-six animals were divided into four groups and treated daily for 13 weeks with an afternoon injection of melatonin (25 micrograms/injection) or saline diluent. ML-23 was given via the drinking water to both melatonin- and saline-treated groups. The experiment was continued until 78% of melatonin-treated animals exhibited acyclicity. The results show that ML-23 partially reversed the effects of melatonin on pituitary follicle-stimulating hormone concentrations but was without effect on the decreased pituitary and plasma prolactin concentrations induced by melatonin treatment. Furthermore, ML-23 antagonized the effects of melatonin on plasma thyroxine levels and significantly increased plasma triiodothyronine concentrations and the free triiodothyronine index when used in combination with melatonin. The decrease in ovarian weight and plasma estradiol, but not progesterone, obtained with melatonin treatment also was reversed by ML-23. Our data suggest that ML-23 prevents the effects of melatonin treatment on ovarian weight, pituitary follicle-stimulating hormone levels, plasma estradiol, and thyroxine concentrations in the female Syrian hamster. Since ML-23 did not prevent the effects of melatonin on pituitary weight, plasma luteinizing hormone and prolactin, and pituitary prolactin concentrations, the actions of ML-23 may involve only peripheral sites of action of melatonin. Alternatively, the dose of ML-23 may not have been optimal to prevent all of the central effects of the indoleamine.

5-Methoxytryptamine↗
PubMed1988

Circadian variations in melatonin-binding sites in discrete areas of the male rat brain.

The binding of 125I-melatonin to synaptosomes prepared from whole brains of male rats of the CD strain and from the brain, hypothalamus and striatum of male rats of the Sabra-Wistar strain was assessed throughout a 24 h period. The animals were maintained under a daily schedule of 14 h light (05:00-19:00 h) and 10 h darkness. In whole brain preparations the density of binding sites at 18:00 h was higher by about 70% than at 02:00 h with no variations in apparent affinity of the binding sites throughout the daily period. Specific binding of 125I-melatonin was found in both hypothalamus and striatum of the male rat with a distinct diurnal variation in binding site density in the hypothalamus only. The density of 125I-melatonin-binding sites in the hypothalamus was maximal between 10:00 and 18:00 h and dropped sharply after the lights went off. The apparent 125I-melatonin-binding affinities in these regions were constant and very similar to those in whole brain preparations. The daily variations in densities of 125I-melatonin-binding sites in discrete brain areas may represent a diurnal rhythmicity in the responsiveness of the neuroendocrine axis to melatonin.

Animals↗
PubMed1988

Melatonin receptors revisited.

The pineal gland and its major product melatonin have a key role in conveying the environmental photoperiodic stimuli that impinge upon the mammalian reproductive axis. The brain, especially the medial preoptic and suprachiasmatic areas are thought to be the main sites of melatonin's neuroendocrine activity. The responsiveness of the mammalian reproductive system to the hormone is dependent on age, on the prevailing cyclical stage and on the circadian time. The existence of specific 125I-melatonin binding sites in synaptosomal fractions from rodent brain has recently been reported. The binding of 125I-melatonin is inhibited by melatonin and by the novel melatonin antagonist ML-23 but not by dopamine, serotonin or other structurally related compounds. The densities of 125I-melatonin binding sites at discrete brain regions vary significantly with age, circulating levels of steroid hormones or circadian time. These phenomena are compatible with the existence of melatonin receptors in the brain.

Animals↗
PubMed1988

Impact of circulating testosterone on iodomelatonin binding sites in the male rat brain.

The effects of castration and subsequent testosterone and estradiol treatment and of a single injection of ethylene-1,2-dimethanesulphonate (EDS) on the distribution of [2-125I]iodomelatonin ([ 125I]melatonin) binding sites in the male rat brain were investigated. Castration produced a marked testosterone-reversible decrease in [125I]melatonin binding in the male rat brain, particularly in the hypothalamus and hippocampus. In contrast, [125I]melatonin binding in the parietal cortex, medulla-pons and cerebellum was generally unaffected by castration. Estradiol did not reverse the effect of castration on [125I]melatonin binding. A single injection of EDS which causes the destruction of Leydig cells led to a marked decrease in [125I]melatonin binding in the brain of the rats between 3 and 7 days after treatment. This decrease correlated with the decline in serum concentrations of testosterone. Specific [125I]melatonin binding and serum concentrations of testosterone subsequently increased to control levels within 37 days after treatment in accord with the repopulation of Leydig cells. The results clearly show that testosterone regulates the density of melatonin receptors in the hypothalamus and hippocampus of the male rat.

Animals↗
PubMed1988

Melatonin receptors in discrete brain areas of the male rat. Impact of aging on density and on circadian rhythmicity.

The distribution of melatonin receptors in six discrete brain areas of mature (3-4 months old) and aged (greater than 24 months old) male rats was recorded every 4 h during a 24-hour light: dark cycle (L:D 14:10h). 125I-melatonin was used as a melatonin receptor probe. In the mature animals, specific binding of 125I-melatonin was found in all brain areas investigated, i.e. hypothalamus, medulla pons, hippocampus, cerebellum, parietal cortex and striatum. The density of 125I-melatonin-binding sites in the hypothalamus, medulla pons and hippocampus exhibited clear diurnal rhythms with different patterns and phases. No such rhythm was evident in the cerebellum, parietal cortex and striatum. The apparent affinity of the binding sites was similar in all the brain regions and did not change at any of the times recorded. In the old male rats, the density of 125I-melatonin binding sites in the hypothalamus was only 10% of that in the mature animals at 13 h after the onset of light and was vanishingly small throughout the 24-hour period. The 24-hour mean of the binding site density in the parietal cortex, hippocampus and medulla pons was significantly lower than in mature rats with no apparent diurnal variations. The age-related decrease in the density of melatonin-binding sites was less pronounced in the cerebellum and striatum. In all brain areas tested, apart from the hypothalamus, the decrease in receptor densities was not accompanied by changes in the apparent affinity towards the ligand.(ABSTRACT TRUNCATED AT 250 WORDS)

Aging↗
PubMed1988

N-(2,4-dinitrophenyl)-5-methoxytryptamine, a novel melatonin antagonist: effects on sexual maturation of the male and female rat and on oestrous cycles of the female rat [corrected].

N-(2,4-dinitrophenyl)-5-methoxytryptamine [corrected] has recently been synthesized and shown to antagonize the inhibitory effect of melatonin on the release of dopamine in vitro from the hypothalamus of female rats. In the present study the ability of N-(2,4-dinitrophenyl)-5-methoxytryptamine [corrected] to inhibit in vivo the following melatonin-mediated effects was investigated: (1) delayed sexual maturation of young male rats, (2) delayed sexual maturation of young female rats, (3) inhibition of ovulation in mature female rats and (4) re-establishment of oestrous cycles in adult female rats maintained in continuous light. The inhibitory effect of daily melatonin injections, given in the afternoon, on the growth of the prostate gland and seminal vesicles and on serum testosterone concentrations in young male rats was prevented by daily injections of N-(2,4-dinitrophenyl)-5-methoxytryptamine [corrected]. Daily injections of N-(2,4-dinitrophenyl)-5-methoxytryptamine [corrected] alone did not affect sexual maturation of young rats. In young male rats treated through the drinking water with melatonin, the growth of the accessory sex organs, but not that of the testes, was delayed and serum concentrations of testosterone were lower than in untreated rats. Administration of N-(2,4-dinitrophenyl)-5-methoxytryptamine [corrected] through the drinking water increased serum concentrations of testosterone but did not significantly affect the weights of the accessory sex organs. Simultaneous administration of N-(2,4-dinitrophenyl)-5-methoxytryptamine [corrected] and melatonin through the drinking water prevented completely, in a dose-dependent manner, the melatonin-mediated decrease in epididymal weights and in serum concentrations of testosterone and partially inhibited the delayed growth of the prostate glands and seminal vesicles. In young female rats treated with melatonin through the drinking water for 30 days, the growth of the ovaries was inhibited and serum concentrations of oestradiol were lower than in untreated rats. The growth of the uterus was not significantly affected. Administration of N-(2,4-dinitrophenyl)-5-methoxytryptamine [corrected] through the drinking water did not significantly affect uterine and ovarian weights or oestradiol concentrations. Simultaneous administration of melatonin and N-(2,4-dinitrophenyl)-5-methoxytryptamine [corrected] through the drinking water prevented completely the melatonin-mediated decrease in ovarian weights and in serum oestradiol concentrations. Ovulation during presumptive oestrus was prevented in adult female rats treated through the drinking water for 7 days with melatonin. Administration of N-(2,4-dinitrophenyl)-5-methoxytryptamine [corrected] alone did not significantly affect the average numbers of ova shed and corpora lutea present. Simultaneous administration of N-(2,4-dinitrophenyl)-5-methoxytryptamine [corrected] and melatonin prevented completely the melatonin-mediated inhibition of ovulation; the average number of ova shed was the same as in controls.(ABSTRACT TRUNCATED AT 400 WORDS)

5-Methoxytryptamine↗
PubMed1987

Impact of circulating estradiol on melatonin binding sites in discrete areas of the female rat brain.

The distribution of 125I-melatonin binding sites in 6 discrete brain regions of female rats at the estrous stage and the effects of ovariectomy and subsequent 17 beta-estradiol treatment on these binding sites were studied. Specific binding of 125I-melatonin was found in the hypothalamus, medulla-pons, hippocampus, cerebellum, striatum and parietal cortex of the female rats. Ovariectomy produced a large estradiol-reversible decrease in 125I-melatonin binding in the medulla-pons and hypothalamus. In contrast, 125I-melatonin binding sites in the other brain regions were generally unaffected by ovariectomy or estradiol. The estradiol-regulated changes in melatonin binding in the hypothalamus and medulla-pons may reflect the role of a specific estradiol-melatonin interaction in the coordination of the neuroendocrine reproductive axis.

Animals↗